Rekovar Inc. Company Profile

Background

Rekovar Inc., founded in 2018, is a privately held medical device company headquartered in Lake Forest, California. The company is dedicated to transforming neonatal care through the development of AI-driven, continuous monitoring systems that integrate audio, visual, and physiological data. Rekovar's primary focus is on addressing critical unmet needs in Neonatal Intensive Care Units (NICUs), with a particular emphasis on Neonatal Abstinence Syndrome (NAS). By combining advanced sensing technologies with artificial intelligence, Rekovar aims to support individualized, data-driven care for newborns, thereby improving patient outcomes and reducing healthcare costs.

Key Strategic Focus

Rekovar's strategic objectives center on the development and commercialization of innovative monitoring solutions for neonates, particularly those affected by NAS. The company's flagship product, the NeoMonki Neonatal Monitoring Kit, is designed to provide real-time, objective assessments of infants' conditions by analyzing physiological, neurological, and behavioral biomarkers. This AI-powered system aims to enhance the accuracy and consistency of NAS assessments, reduce hospital readmissions, shorten NICU stays, and optimize therapeutic interventions. Rekovar's primary markets include hospitals, NICUs, and home healthcare settings, where the need for reliable and efficient neonatal monitoring solutions is paramount.

Financials and Funding

Rekovar has secured significant funding to support its research and development initiatives. In July 2022, the company was awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Drug Abuse (NIDA), totaling $2.5 million. This funding represents a 106% increase from the initial $1,215,174 award and is intended to propel the development and commercialization of Rekovar's wireless withdrawal detection and monitoring system for NAS. Additionally, in June 2021, Rekovar received a $280,000 grant from NIDA to further its research efforts. These funds are being utilized to advance the company's technology, conduct clinical trials, and prepare for market entry.

Pipeline Development

Rekovar's primary product in development is the NeoMonki Neonatal Monitoring Kit, a comprehensive system designed to provide continuous, real-time monitoring of infants diagnosed with NAS. The kit includes an infant wearable wristband, an imaging camera, a recharging station, a tablet application, and a patient portal tailored for healthcare providers. The system leverages AI to analyze physiological, neurological, and behavioral biomarkers, aiming to improve the accuracy and consistency of NAS assessments. Rekovar has completed the feasibility readiness phase for this system and is progressing towards clinical trials to validate its efficacy and safety.

Technological Platform and Innovation

Rekovar's innovation lies in its integration of wearable biosensor technology with advanced AI and machine learning algorithms to monitor and assess neonates' health. The NeoMonki system utilizes proprietary technologies to continuously collect and analyze data, providing healthcare professionals with objective, data-driven insights into the physiological states of newborns. This approach aims to improve the accuracy of NAS diagnoses, optimize treatment protocols, and reduce the length of hospital stays. Rekovar's commitment to quality and safety is demonstrated by its ISO 13485 certification for medical devices, ensuring that its products meet international standards for quality management systems.

Leadership Team

Rekovar's leadership team comprises experienced professionals with diverse backgrounds in healthcare, technology, and business development:

• Shiva Sharareh, PhD: Chief Executive Officer & Founder.

• Jim Schulz, CPA: Chief Financial Officer.

• Raj Pendekanti, PhD: Vice President of Engineering and Manufacturing.

• Arman Onbirbak: Business Development.

The team is supported by a Clinical Advisory Board and Technical Advisors, including experts such as Dr. Anthony Chang, Chief Intelligence and Innovation Officer at Children's Hospital Orange County, and Dr. Sudeep Kukreja, Medical Director of Neonatology Intensive Care at the same institution.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Rekovar's leadership team.

Competitor Profile

Market Insights and Dynamics

The neonatal monitoring market is experiencing growth due to increasing incidences of neonatal conditions such as NAS, advancements in medical technology, and a heightened focus on improving neonatal care. The integration of AI and machine learning in healthcare is further driving innovation in this sector.

Competitor Analysis

Rekovar operates in a competitive landscape with several key players:

• Empatica: An Italian company specializing in wearable devices for medical research, focusing on human behavior monitoring.

• Elfi-Tech: An Israeli firm developing non-invasive monitoring technologies for physiological parameters.

• MyndYou: An Israeli company offering mobile-based platforms for monitoring cognitive, physiological, and behavioral parameters.

These competitors focus on various aspects of health monitoring, but Rekovar's emphasis on neonatal care, particularly NAS, and its integration of AI-driven solutions, positions it uniquely in the market.

Strategic Collaborations and Partnerships

Rekovar has established significant collaborations to enhance its technological capabilities and market reach:

• NVIDIA Inception Program: In December 2024, Rekovar joined NVIDIA's Inception Program, gaining access to resources such as AWS credits, expert guidance, and networking opportunities to accelerate its AI-driven solutions.

• Clinical Partnerships: Rekovar has collaborated with institutions like Children's Hospital Orange County (CHOC) for pilot studies and is expanding its clinical trials to include Johns Hopkins University and the University of New Mexico.

Operational Insights

Rekovar's strategic considerations include:

• Market Position: Focusing on the underserved area of NAS monitoring, providing a unique value proposition.

• Competitive Advantages: Integration of AI and wearable technology, ISO 13485 certification, and strong clinical partnerships.

• Differentiators: Comprehensive monitoring solutions that combine physiological, neurological, and behavioral data for individualized neonatal care.

Strategic Opportunities and Future Directions

Rekovar's strategic roadmap includes:

• Product Development: Advancing the NeoMonki system through clinical trials and obtaining regulatory approvals.

• Market Expansion: Targeting additional healthcare facilities and exploring international markets.

• Technological Innovation: Continuing to integrate advanced AI and machine learning capabilities to enhance product offerings.

• Collaborations: Strengthening existing partnerships and establishing new alliances to support research, development, and commercialization efforts.

Contact Information

• Website: www.rekovar.com

• LinkedIn: Rekovar Inc.

• Twitter: @RekovarInc

• Facebook: Rekovar

Rekovar Inc. continues to make significant strides in neonatal healthcare, leveraging cutting-edge technology and strategic partnerships to address critical challenges in the field.